JAZZ News and Press, Jazz Pharmaceuticals plc From 05/05/22

Jazz Pharmaceuticals plc (JAZZ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Andrea Flynn – Head-Investor Relations Bruce Cozadd – Chairman and Chief Executive Officer Dan Swisher – President Rob Iannone – Executive Vice President, G...

Jazz Pharmaceuticals press release (NASDAQ:JAZZ): Q1 Non-GAAP EPS of $3.73 misses by $0.16. Revenue of $813.72M (+33.9% Y/Y) misses by $40.01M. The Company is raising its full year 2022 financial guidance as follows: Revenues of $3,500M - $3,700M (prior $3,460M - $3,660M) vs. consensus o...

Jazz Pharmaceuticals Announces First Quarter 2022 Financial Results and Raises 2022 Financial Guidance PR Newswire DUBLIN , May 4, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2022...

Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist PR Newswire Jazz licenses development and commercialization rights in U.S., Europe and oth...

Jazz Pharmaceuticals to Participate in the BofA Securities 2022 Global Healthcare Conference PR Newswire DUBLIN , May 3, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the BofA Securities ...

The Polaris International Equity Composite returned -5.24%. Now with ‘higher inflation for longer’ rhetoric, commodities have another leg up as in the past they have served as a hedge against inflation. We are considering the risks of a big slowdown in Europe, contin...

The Polaris Global Equity Composite returned -3.83%. We are constantly assessing the portfolio seeking to ensure that our holdings thrive in an inflationary period. We are actively seeking attractively-priced stocks with good upside potential and lesser downside risk. We belie...

Cannabinoids, such as cannabidivarin (CBDV) could be a therapeutic game-changer. In fact, according to InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Eric Hsu, SVP, Pre-Clinical Research and Development for InMed commented; “Cannabinoids hold tremendous therapeutic potential t...

Cannabinoids, such as cannabidivarin (CBDV) may be rare, but may also have exciting potential. In fact, according to InMed Pharmaceuticals Inc. (NASDAQ: INM), “CBDV is one of the most studied rare cannabinoids and has been the subject of research in autism, epilepsy, acne, alopec...

Jazz Pharmaceuticals to Report 2022 First Quarter Financial Results on May 4, 2022 PR Newswire DUBLIN , April 20, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 first quarter financial results on ...